Holen Sie sich die Stockscreener-App
2.125
1.19%
0.025
Schlusskurs vom Vortag:
$2.10
Offen:
$2.11
24-Stunden-Volumen:
1.91M
Relative Volume:
0.50
Marktkapitalisierung:
$563.43M
Einnahmen:
$194.75M
Nettoeinkommen (Verlust:
$-51.26M
KGV:
-7.5893
EPS:
-0.28
Netto-Cashflow:
$-23.38M
1W Leistung:
-29.87%
1M Leistung:
-22.16%
6M Leistung:
-11.83%
1J Leistung:
+28.01%
1-Tages-Spanne:
$2.07
$2.20
1-Wochen-Bereich:
$2.065
$3.20
52-Wochen-Spanne:
$1.52
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Firmenname
Akebia Therapeutics Inc
Sektor
Telefon
617-871-2098
Adresse
245 FIRST STREET, CAMBRIDGE, MA
Vergleichen Sie AKBA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
2.125 | 556.80M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
142.79 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.42 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.2309 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.09 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
447.93 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-04-28 | Eingeleitet | Leerink Partners | Outperform |
| 2025-04-01 | Eingeleitet | Jefferies | Buy |
| 2023-11-29 | Fortgesetzt | BTIG Research | Buy |
| 2023-08-28 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-31 | Herabstufung | Needham | Buy → Hold |
| 2022-03-31 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-01-29 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-14 | Bestätigt | Needham | Buy |
| 2019-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2019-07-11 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-02 | Eingeleitet | JP Morgan | Overweight |
| 2019-03-20 | Eingeleitet | Citigroup | Neutral |
| 2018-09-07 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2018-08-10 | Bestätigt | Needham | Buy |
| 2018-06-06 | Bestätigt | H.C. Wainwright | Buy |
| 2017-12-19 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-12-07 | Eingeleitet | BTIG Research | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-27 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-27 | Bestätigt | Needham | Buy |
| 2016-12-27 | Bestätigt | H.C. Wainwright | Buy |
| 2016-12-20 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-11-15 | Eingeleitet | Aegis Capital | Buy |
| 2016-09-29 | Eingeleitet | Brean Capital | Buy |
| 2016-03-16 | Bestätigt | Needham | Buy |
| 2016-01-21 | Eingeleitet | Credit Suisse | Neutral |
Alle ansehen
Akebia Therapeutics Inc Aktie (AKBA) Neueste Nachrichten
Akebia Therapeutics (NASDAQ:AKBA) Price Target Lowered to $6.00 at HC Wainwright - MarketBeat
How high can Akebia Therapeutics Inc. stock goWeekly Profit Analysis & Expert Curated Trade Setup Alerts - newser.com
Akebia Therapeutics (AKBA) Expected to Announce Earnings on Thursday - MarketBeat
Is Akebia Therapeutics Inc. (AX9) stock attractive for growth fundsJuly 2025 Pullbacks & AI Forecasted Entry and Exit Points - newser.com
Can Akebia Therapeutics Inc. stock sustain revenue growth2025 Buyback Activity & Consistent Profit Alerts - newser.com
Why Akebia Therapeutics Inc. (AX9) stock attracts wealthy investorsJuly 2025 Recap & Free Technical Pattern Based Buy Signals - newser.com
How rising interest rates impact Akebia Therapeutics Inc. stockMarket Activity Report & High Accuracy Buy Signal Tips - newser.com
Will Akebia Therapeutics Inc. stock attract more institutional investorsWeekly Trade Recap & Weekly Hot Stock Watchlists - newser.com
Is Akebia Therapeutics Inc. (AX9) stock attractive for dividend growthJuly 2025 News Drivers & Expert Verified Stock Movement Alerts - newser.com
Akebia Therapeutics (AKBA) Is Down 29.9% After Ending VALOR Trial for Non-Dialysis CKD Patients - Yahoo Finance
Akebia Therapeutics (NASDAQ:AKBA) Price Target Lowered to $5.00 at BTIG Research - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Shares Gap DownHere's Why - MarketBeat
How Akebia Therapeutics Inc. stock trades during market volatilityInsider Buying & Stepwise Trade Signal Guides - newser.com
Akebia Therapeutics (AKBA) Receives Revised Price Target from HC Wainwright & Co. | AKBA Stock News - GuruFocus
Akebia Therapeutics to Report Third Quarter 2025 Financial Results and Discuss Recent Business Highlights - MarketScreener
HC Wainwright & Co. Maintains Akebia Therapeutics (AKBA) Buy Recommendation - Nasdaq
How strong dollar benefits Akebia Therapeutics Inc. (AX9) stock2025 Big Picture & Fast Gain Swing Alerts - newser.com
Strategic Shift and Market Opportunities Drive Buy Rating for Akebia Therapeutics - TipRanks
Is Akebia Therapeutics Inc. (AX9) stock undervalued at current priceMarket Rally & Smart Money Movement Tracker - newser.com
Akebia price target lowered to $6 from $8 at H.C. Wainwright - TipRanks
Will Akebia Therapeutics Inc. stock benefit from sector rotationJuly 2025 Breakouts & High Yield Equity Trading Tips - newser.com
Will Akebia Therapeutics Inc. (AX9) stock profit from AI boomTrade Risk Report & AI Based Buy and Sell Signals - newser.com
Health Care Down on Mixed EarningsHealth Care Roundup - MarketScreener
BTIG Lowers Akebia Therapeutics (AKBA) Price Target by 50% | AKB - GuruFocus
Why Is Akebia Therapeutics Stock Plunging TodayAkebia Therapeutics (NASDAQ:AKBA) - Benzinga
Akebia Therapeutics: Dialysis-Only Path Puts VOCAL/Protocol Wins At The Core (NASDAQ:AKBA) - Seeking Alpha
Akebia Therapeutics’ Pediatric Anemia Study Withdrawn: Market Implications - TipRanks
Akebia stock plunges as kidney drug expansion plans scrapped - The Business Journals
Akebia scraps plan for Vafseo trial after discussions with FDA - Fierce Pharma
Akebia Therapeutics Stock Slumps After FDA Meeting Ends Without Path Forward for Vafseo Label Expansion - Stocktwits
Akebia stock tumbles after FDA meeting on vadadustat trial design By Investing.com - Investing.com Canada
Akebia Abandons Non-Dialysis Trial For Vafseo On Likely Higher Costs - Citeline News & Insights
Mondelez International, Stride, Varonis Systems And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Morning Market Movers: CMBM, LRN, VRNS, AKBA See Big Swings - RTTNews
FDA setback prompts Akebia to give up on broader Vafseo label - The Pharma Letter
Why Teradyne Shares Are Trading Higher By More Than 20%; Here Are 20 Stocks Moving Premarket - Benzinga
Will earnings trigger a reversal in Akebia Therapeutics Inc.July 2025 Breakouts & Long Hold Capital Preservation Plans - newser.com
Why institutional investors increase stakes in Akebia Therapeutics Inc. (AX9) stockAnalyst Downgrade & Long Hold Capital Preservation Tips - newser.com
Analyzing Akebia Therapeutics Inc. with risk reward ratio chartsPortfolio Return Report & Community Trade Idea Sharing - newser.com
Comparing Akebia Therapeutics Inc. in custom built stock radarsExit Point & AI Driven Price Predictions - newser.com
Is Halting Broad Vafseo Expansion Shifting the Investment Outlook for Akebia Therapeutics (AKBA)? - simplywall.st
Akebia Therapeutics (AKBA) Halts Expansion Plans for Vafseo - GuruFocus
Akebia (AKBA) Adjusts Strategy Following FDA Meeting on Anemia T - GuruFocus
Earnings Beat: Will Akebia Therapeutics Inc. stock benefit from sector rotationMarket Performance Recap & Technical Pattern Alert System - Fundação Cultural do Pará
Akebia plummets as it abandons Vafseo for non-dialysis patients - Seeking Alpha
Akebia Therapeutics tumbles after FDA setback on anemia drug trial - TradingView
Akebia Therapeutics Halts VALOR Trial for Vadadustat - TipRanks
Akebia Therapeutics provides update on Vafseo for non-dialysis patients - MarketScreener
Akebia Therapeutics Inc Updates on Vafseo Clinical Trial Plans - TradingView
Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients - The Manila Times
Akebia (NASDAQ: AKBA) to forgo broad Vafseo label in NDD‑CKD post FDA Type C meeting - Stock Titan
Finanzdaten der Akebia Therapeutics Inc-Aktie (AKBA)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.86%
1.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):